cannabis indica

Perda de Apetite

termo de indexação original: Loss of Appetite

O acervo do Cannabis Indica reúne 59 estudos científicos que tocam a condição Perda de Apetite, publicados entre 1994 e 2024. Pela leitura automatizada, 44 (75%) foram classificados como favoráveis, 9 (15%) como inconclusivos e 6 (10%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (26 estudos), seguido de ensaio clínico (13). Os compostos mais presentes são THC Farmacêutico, Tetraidrocanabinol (THC) e 2-Araquidonoilglicerol (2-AG). Aparece com frequência ao lado de Anorexia (perda de apetite), Dor e Câncer.

Estudos indexados
59
Período coberto
1994–2024
Favoráveis
44 · 75%
Inconclusivos
9 · 15%
Desfavoráveis
6 · 10%
Termo original
Loss of Appetite

O acervo em números

Tipo de estudo

Metanálise26
Ensaio Clínico13
Ensaio Clínico Duplo-Cego8
Estudo em Animais6
Metanálise Clínica5
Estudo Laboratorial1

Direção do resultado

Favorável44
Inconclusivo9
Desfavorável6

Por década

1990s2
2000s4
2010s30
2020s23

59 estudos

Filtrar e buscar no acervo →
  1. 2024

    The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature

    FavorávelMetanálise ClínicaQualidade de Vida
  2. 2023

    A systematic review of cannabidiol trials in neurodevelopmental disorders

    FavorávelMetanálise ClínicaDorInflamaçãoAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+10
  3. 2023

    Cannabinoid receptor type 1 (CB1R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3

  4. 2023

    Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis

    InconclusivoMetanálise ClínicaDorDependência QuímicaCâncer+15
  5. 2023

    Cannabis-Induced Acute Encephalopathy in a 94-Year-Old Woman Due to Family Administration of Cannabidiol (CBD) Products: A Case Report

  6. 2023

    Could cannabinoids provide a new hope for ovarian cancer patients?

  7. 2023

    Ulceration and a White Lesion of the Tongue in a Male HIV Positive Patient: A Journey on the Avenue of Differential Diagnoses in Search of a Solution

    DesfavorávelMetanáliseDorInflamaçãoEfeitos Adversos da CannabisMicrobioma+6
  8. 2022

    Cannabinoids as anticancer drugs: current status of preclinical research

  9. 2022

    Cannabis in Palliative Care: A Systematic Review of Current Evidence

    InconclusivoMetanáliseCâncerEpilepsiaInsônia e Distúrbios do Sono+6
  10. 2022

    Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

    FavorávelMetanáliseAnsiedadeEpilepsiaObesidadeTetraidrocanabinol (THC)+5
  11. 2022

    Impact of Antiseizure Medications on Appetite and Weight in Children

    InconclusivoMetanálise ClínicaEpilepsia
  12. 2022

    Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study

    FavorávelEnsaio ClínicoInflamaçãoAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+6
  13. 2022

    Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways

    FavorávelEstudo em AnimaisCâncerInflamaçãoDoenças Cardiovasculares (DCV)+6
  14. 2022

    Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants

  15. 2021

    A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease: What Can We Learn From Randomized and Nonrandomized Studies?

    DesfavorávelMetanáliseDorNáusea e VômitoDiarreia
  16. 2021

    Adverse Effects of Recreational and Medical Cannabis

    InconclusivoMetanáliseDorEfeitos Adversos da CannabisDor — Crônica+2
  17. 2021

    Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis

  18. 2021

    Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

  19. 2021

    Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey

    FavorávelMetanáliseDorCâncerInsônia e Distúrbios do Sono+2
  20. 2021

    Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

  21. 2021

    Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review

    InconclusivoMetanáliseDorAnsiedadeDor — Crônica+3
  22. 2021

    Vape-Associated Pulmonary Injury (VAPI) Presenting With a "Miliary" Pattern on Imaging

    DesfavorávelMetanáliseInflamaçãoEfeitos Adversos da CannabisNáusea e Vômito+3
  23. 2020

    Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

  24. 2019

    A hunger for hunger: A review of palliative therapies for cancer-associated anorexia

    FavorávelMetanáliseAnorexia (perda de apetite)
  25. 2019

    Chemotherapy‐induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol

  26. 2019

    Effect of acute Δ9-tetrahydrocannabinol administration on subjective and metabolic hormone responses to food stimuli and food intake in healthy humans: a randomized, placebo-controlled study

  27. 2019

    Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials

    FavorávelMetanáliseCâncerInflamaçãoAnorexia (perda de apetite)Ômega-3+3
  28. 2019

    Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Síndrome de DravetDiarreiaCBD Farmacêutico+1
  29. 2018

    A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms

  30. 2018

    Cannabinoid Receptor Signaling in Central Regulation of Feeding Behavior: A Mini-Review

  31. 2018

    Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia

    FavorávelMetanáliseDoenças NeurodegenerativasDoença de Alzheimer
  32. 2018

    Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation

    FavorávelMetanáliseSíndrome Metabólica
  33. 2018

    Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer

  34. 2018

    Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders

    InconclusivoMetanáliseEsquizofreniaObesidadeSíndrome Metabólica
  35. 2018

    Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

    FavorávelEnsaio Clínico Duplo-CegoEpilepsiaNáusea e VômitoEpilepsia — Síndrome de Dravet
  36. 2018

    Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity-related Disorders

  37. 2018

    Salivary endocannabinoids and N-acylethanolamines upon mastication of a semisolid food: implications in fat taste, appetite and food liking

    InconclusivoEnsaio Clínico Duplo-Cego2-Araquidonoilglicerol (2-AG)
  38. 2018

    The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial

    FavorávelEnsaio Clínico Duplo-CegoDorInsônia e Distúrbios do SonoAnorexia (perda de apetite)THC Farmacêutico+4
  39. 2017

    Consequence of dopamine D2 receptor blockade on the hyperphagic effect induced by cannabinoid CB1 and CB2 receptors in layers

    FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)
  40. 2016

    Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation

    FavorávelMetanáliseCâncerAnorexia (perda de apetite)
  41. 2016

    Got Munchies? Estimating the Relationship between Marijuana Use and Body Mass Index.

    FavorávelMetanáliseObesidadeDiabetesSíndrome Metabólica
  42. 2015

    A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial

    FavorávelEnsaio Clínico Duplo-CegoDorDoenças Cardiovasculares (DCV)Dor — AgudaTHC Farmacêutico+3
  43. 2015

    Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial

    InconclusivoEnsaio Clínico Duplo-CegoDorCâncerInsônia e Distúrbios do SonoTHC Farmacêutico+5
  44. 2015

    MDMA, cannabis, and cocaine produce acute dissociative symptoms

    DesfavorávelEnsaio ClínicoDependência QuímicaEfeitos Adversos da CannabisAnsiedade+7
  45. 2015

    Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers

    FavorávelEnsaio Clínico Duplo-CegoObesidadeTetraidrocanabivarina (THCV)
  46. 2015

    Therapeutic potential of cannabinoids in counteracting chemotherapy-induced adverse effects: an exploratory review.

    FavorávelMetanáliseDorCâncerDoenças Cardiovasculares (DCV)+9
  47. 2013

    A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain

    FavorávelEnsaio ClínicoDorCâncerAnsiedadeTHC:CBD Farmacêutico+5
  48. 2013

    Addition of capsaicin and exchange of carbohydrate with protein counteract energy intake restriction effects on fullness and energy expenditure

  49. 2013

    Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs

    FavorávelEstudo em AnimaisDorCâncerPsicoseTHC Farmacêutico+10
  50. 2013

    Effects of the Cannabinoid-1 Receptor Antagonist/Inverse Agonist Rimonabant on Satiety Signaling in Overweight People with Schizophrenia

  51. 2012

    An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics

  52. 2011

    A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

  53. 2011

    Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial

    FavorávelEnsaio Clínico Duplo-CegoDorCâncerInflamaçãoTHC Farmacêutico+9
  54. 2008

    Open-Label, Add-on Study of Tetrahydrocannabinol for Chronic Nonmalignant Pain

  55. 2005

    Dronabinol, a possible new therapeutic option in patients with COPD and pulmonal cachexia

    FavorávelEnsaio ClínicoAnorexia (perda de apetite)CaquexiaDPOC
  56. 2003

    Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716

    FavorávelEstudo em AnimaisAnandamida (AEA)Tetraidrocanabinol (THC)+2
  57. 2002

    Tetrahydrocannabinol and endocannabinoids in feeding and appetite

  58. 1997

    Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia

    FavorávelEnsaio ClínicoAnorexia (perda de apetite)HIV/AIDSCaquexiaTHC Farmacêutico
  59. 1994

    A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia.

Continue por aqui

Perguntas frequentes

Quantos estudos sobre perda de apetite estão indexados no acervo?
São 59 estudos, publicados entre 1994 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 26 · Ensaio Clínico: 13 · Ensaio Clínico Duplo-Cego: 8 · Estudo em Animais: 6 · Metanálise Clínica: 5 · Estudo Laboratorial: 1. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 44 favoráveis, 9 inconclusivos e 6 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Perda de Apetite — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/perda-de-apetite/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Perda de Apetite — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/perda-de-apetite/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.